Publication:
Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections

Simple item page
dc.contributor.authorRujipas Sirijatuphaten_US
dc.contributor.authorVisanu Thamlikitkulen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-11-09T02:51:51Z
dc.date.available2018-11-09T02:51:51Z
dc.date.issued2014-01-01en_US
dc.description.abstractNinety-four patients infected with carbapenem-resistant Acinetobacter baumannii were randomized to receive colistin alone or colistin plus fosfomycin for 7 to 14 days. The patients who received combination therapy had a significantly more favorable microbiological response and a trend toward more favorable clinical outcomes and lower mortality than those who received colistin alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01297894.) Copyright © 2014, American Society for Microbiology. All Rights Reserved.en_US
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Vol.58, No.9 (2014), 5598-5601en_US
dc.identifier.doi10.1128/AAC.02435-13en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-84906080468en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/34603
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84906080468&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePreliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infectionsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84906080468&origin=inwarden_US

Files

Collections

Scopus 2011-2015